arrow
D

Dale J. Kempf

Abbott Laboratories
H指数:59
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis
2023-04-182
OAAI
The Tuberculosis Drug Accelerator at year 10: what have we learned?
2021-07-0539
OAAI
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth

具有改善的hERG和细胞毒性特征的Spirocycle MmpL3抑制剂作为结核分枝杆菌生长的抑制剂

2021-01-1325
OAAI
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned
2020-05-0140
OAAI
Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis
2019-03-1359
OAAI
Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity
2019-02-2827
OAAI
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
2018-01-0169
OAAI
Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis
2017-10-0130
OAAI
Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis
2016-10-1781
OAAI
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis
2016-07-0178
OAAI
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1
2015-10-2636
OAAI